Obesity remains one of the most prevalent and costly chronic conditions in the U.S., yet access to effective treatment continues to lag—largely due to high medication costs, fragmented care models, and restrictive benefit designs. While GLP-1 and other anti-obesity medications have transformed clinical outcomes, their price has forced many employers and plans into an untenable tradeoff between access and affordability.
Join Vida Health, RxSaveCard, and Rock Health Advisory for a thought-provoking discussion on how the industry can move beyond this false choice. This session will explore how innovative pricing mechanisms, integrated care delivery, and evolving benefit strategies can expand access to obesity care—without compromising financial sustainability. Panelists will examine what's changing in the market, what's still broken, and what employers, plans, and partners can do now to unlock more equitable, effective obesity treatment.
Key Takeaways
- The Access Imperative: Why expanding access to obesity care is a clinical, economic, and workforce priority—and the risks of maintaining the status quo.
- Cost Isn't the Only Barrier: How benefit design, utilization management, and care fragmentation compound affordability challenges beyond drug price alone.
- Integrated Care as a Force Multiplier: How combining medical oversight, nutrition therapy, behavior change support, and medication optimization improves outcomes and ROI.
- Innovative Affordability Models: The role of savings programs, alternative pricing approaches, and nontraditional partnerships in lowering member out-of-pocket costs.
- What's Next for Employers: Practical considerations for designing obesity benefits that scale access today while remaining adaptable as pricing, policy, and evidence evolve.
As demand for obesity treatment continues to grow, the question is no longer whether access must expand—but how to do so responsibly. Join us for a forward-looking conversation on what it will take to make effective obesity care accessible to more people, even in a high-cost environment.
